Abstract
Background: The association between albuminuria and coronary heart disease (CHD) is well-known, but uncertainties related to day-to-day variability and effect modification of gender complicate the risk assessment process. This study evaluates the associations of CHD with albuminuria level in men and women based on the number of urine samples. Methods: Nine thousand one hundred and fifty-eight adults provided 3 urine samples and were followed for 14 years in the population-based HUNT-2 cohort study. The association of myocardial infarction or coronary death with different albumin-creatinine ratio (ACR) cut-offs, based on gender and number of positive ACRs, were estimated by hazard ratios (HRs) and adjusted for by Framingham variables. Results: Associations between ACR and CHD were similar in men and women. For example, HRs for moderately increased (3.0≤ ACR ≤30.0 mg/mmol) vs. normal albuminuria (ACR <1.0 mg/mmol) were 1.40 (95% CI 1.27-2.03) and 1.61 (95% CI 1.15-1.71) respectively, (psex-equality = 0.3). However, median intra-individual day-to-day ACR coefficient of variation was 22.4% in women vs. 17.5% in men (p < 0.001). Two or 3 positive ACRs were required to establish a significant association with CHD at levels below 4.0 mg/mmol in women, while one positive ACR implied a significant association at all levels in men. Based on receiver-operating-characteristics curves, the Youden index suggested possible equal cut-offs for women (1.12 mg/mmol) and men (0.88 mg/mmol), p = 0.06. Conclusions: There were no significant gender differences in the association between albuminuria and coronary events. However, women had increased intra-individual albuminuria variability compared to men, necessitating several positive urine samples if mildly increased albuminuria is used in coronary risk evaluation.
References
1.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2014 update: a report from the American heart association. Circulation 2014;129:e28-e292.
2.
Nichols M, Townsend N, Scarborough P, Rayner M: Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013;34:3028-3034.
3.
Chen J, Normand SL, Wang Y, Drye EE, Schreiner GC, Krumholz HM: Recent declines in hospitalizations for acute myocardial infarction for Medicare fee-for-service beneficiaries: progress and continuing challenges. Circulation 2010;121:1322-1328.
4.
Sulo G, Vollset SE, Nygård O, Igland J, Egeland GM, Ebbing M, Tell GS: Trends in acute myocardial infarction event rates and risk of recurrences after an incident event in Norway 1994 to 2009 (from a cardiovascular disease in Norway project). Am J Cardiol 2014;113:1777-1781.
5.
Towfighi A, Markovic D, Ovbiagele B: National gender-specific trends in myocardial infarction hospitalization rates among patients aged 35 to 64 years. Am J Cardiol 2011;108:1102-1107.
6.
Mannsverk J, Wilsgaard T, Njolstad I, Hopstock LA, Lochen ML, Mathiesen EB, Thelle DS, Rasmussen K, Bonaa KH: Age and gender differences in incidence and case fatality trends for myocardial infarction: a 30-year follow-up. The Tromso study. Eur J Prev Cardiol 2012;19:927-934.
7.
Lloyd-Jones DM: Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 2010;121:1768-1777.
8.
Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-2081.
9.
Jensen JS: Intra-individual variation of overnight urinary albumin excretion in clinically healthy middle-aged individuals. Clin Chim Acta 1995;243:95-99.
10.
Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ: Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis 2013;62:1095-1101.
11.
James GD, Sealey JE, Alderman M, Ljungman S, Mueller FB, Pecker MS, Laragh JH: A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens 1988;1:124-131.
12.
Clinical Guidelines Task Force: Global Guideline for Type 2 Diabetes. International Diabetes Federation, 2012.
13.
Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Chadban SJ, Usherwood T, Polkinghorne K, Colagiuri S, Jerums G, Macisaac R, Martin H; Australasian Proteinuria Consensus Working Group: Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Med J Aust 2012;197:224-225.
14.
Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996;7:930-937.
15.
KDIGO: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'. Kidney Int Suppl 2013;3:136-150.
16.
Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, Iseki K, Jassal SK, Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, Hemmelgarn BR; Chronic Kidney Disease Prognosis Consortium: Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013;346:f324.
17.
Hui X, Matsushita K, Sang Y, Ballew SH, Fulop T, Coresh J: CKD and cardiovascular disease in the atherosclerosis risk in communities (ARIC) study: interactions with age, sex, and race. Am J Kidney Dis 2013;62:691-702.
18.
Hallan H, Romundstad S, Kvenild K, Holmen J: Microalbuminuria in diabetic and hypertensive patients and the general population - consequences of various diagnostic criteria - the Nord-Trøndelag Health Study (HUNT). Scand J Urol Nephrol 2003;37:151-158.
19.
Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, Bratberg G, Heggland J, Holmen J: Cohort profile: the HUNT study, Norway. Int J Epidemiol 2013;42:968-977.
20.
Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M, Warnock DG, Wen CP, Coresh J, Gansevoort RT, Hemmelgarn BR, Levey AS; Chronic Kidney Disease Prognosis Consortium: Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012;307:1941-1951.
21.
Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined - a consensus document of the joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.
22.
Statistics Norway, Oslo: www.ssb.no.
23.
Altman DG: Practical Statistics for Medical Research, 1999.
24.
Pencina MJ, Larson MG, D'Agostino RB: Choice of time scale and its effect on significance of predictors in longitudinal studies. Stat Med 2007;26:1343-1359.
25.
Thiébaut AC, Bénichou J: Choice of time-scale in Cox's model analysis of epidemiologic cohort data: a simulation study. Stat Med 2004;23:3803-3820.
26.
Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS: Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 2009;119:3078-3084.
27.
Portney LG, Watkins MP: Foundations of Clinical Research: applications to Practice, ed 3. Upper Saddle River, Prentice-Hall, 2008.
28.
Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577.
29.
Rota M, Antolini L, Valsecchi MG: Optimal cut-point definition in biomarkers: the case of censored failure time outcome. BMC Med Res Methodol 2015;15:24.
30.
Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005;112:969-975.
31.
Mattix HJ, Hsu CY, Shaykevich S, Curhan G: Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002;13:1034-1039.
32.
Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H: Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trøndelag Health Study (HUNT), Norway. Circulation 2003;108:2783-2789.
33.
Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, Itoh Y, Lieske JC, Seccombe DW, Jones G, Bunk DM, Curhan GC, Narva AS; National Kidney Disease Education Program-IFCC Working Group on Standardization of Albumin in Urine: Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009;55:24-38.
34.
Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-360.
35.
Howey JE, Browning MC, Fraser CG: Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation. Clin Chem 1987;33:2034-2038.
36.
Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, Frøland A, Hansen KW, Nielsen S, Pedersen MM: Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995;18:572-581.
37.
Hatlen G, Romundstad S, Hallan SI: The accuracy of predicting cardiovascular death based on one compared to several albuminuria values. Kidney Int 2014;85:1421-1428.
38.
Brinkman JW, de Zeeuw D, Gansevoort RT, Duker JJ, Kema IP, de Jong PE, Bakker SJ: Prolonged frozen storage of urine reduces the value of albuminuria for mortality prediction. Clin Chem 2007;53:153-154.
39.
Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ: Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57:1096-1103.
40.
Alfsen GC, Maehlen J: The value of autopsies for determining the cause of death. Tidsskr Nor Laegeforen 2012;132:147-151.
41.
Lloyd-Jones DM, Martin DO, Larson MG, Levy D: Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med 1998;129:1020-1026.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
